Roche's drugs business brought in CHF 11.47 billion (nearly $14 billion) in the three months, slightly ahead of analyst ...

The AD-SMART trial – which has started to recruit people aged over 55 with a diagnosis of Alzheimer's or mixed dementia – ...

Julia Jakl is VP and Business Unit Head, Oncology UK at GSK. With more than a decade of experience across oncology and ...

Reforms to the regulatory framework for clinical research in the UK are starting to deliver, with delivery times slashed by ...

Waterhouse is due to take the helm of CSL on 1st February next year, around a year after Paul McKenzie abruptly departed the ...

Despite a string of US policy initiatives designed to curb medicine pricing under recent administrations, the annual cost of ...

The FDA has published its long-awaited update to guidance to make sure clinical trials more closely reflect the range of patients that might be treated with a new therapy in the real world. The draft ...

Hibsago, has been approved in the US, its second major market after Japan, giving patients hope of a functional cure without ...

The EMA's human medicines committee has started a review of oral complement C5 inhibitor Tavneos, prompted by information that the regulator says raises questions about the integrity of the data from ...

US MFN rules and new tariffs are narrowing the US–ex-US price gap and drawing more manufacturing and capital investment toward the United States. Low European or UK list prices now directly affect US ...

Novo continues to build the case for its new weight-loss candidate CagriSema, pointing to new data that show strong efficacy ...

That one chance rests on a set of decisions about data and the systems that hold it. Those decisions are usually made quickly ...